Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Pricing Support for Startups: Chuikyo
November 28, 2017
- MHLW Unveils Gx Pricing Plans, Wants to Rectify Distortion by Cutting Oral AG Price: Chuikyo
November 28, 2017
- MHLW Panel Backs Approval for AZ’s Olaparib, Benralizumab and More
November 28, 2017
- CEA-Based Price Tweak Likely to Cover Premium Portion, Not Total Price; Price Raise Also Proposed: Chuikyo
November 28, 2017
- MHLW Proposes Expansion of “Essential Drug” Category to Include Crude Drugs, Ointment Bases, Local Dental Anesthetics and More: Chuikyo
November 28, 2017
- MHLW Proposes Tacking Premiums on Total Drug Price under Cost Calculation Formula: Chuikyo
November 27, 2017
- New Price Cut Scheme for Off-Patent Meds Proposed with Mitigation Plans, but Payer Reps Say Gx Transition Too Slow: Chuikyo
November 24, 2017
- Quarterly Market Expansion Re-Pricing Pitched for 35-Plus Billion Yen Products: Chuikyo
November 24, 2017
- MHLW Proposes Post-Launch Foreign Price Adjustments: Chuikyo
November 24, 2017
- Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
- Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
- MHLW Advisory Panel to Review Otsuka’s Schizophrenia Med Brexpiprazole on Dec. 4
November 22, 2017
- In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
November 20, 2017
- Health Sciences Council’s Panel Approves Basic Framework for “Guidelines,” “Plans” for COI Management in “Specified Clinical Research”
November 20, 2017
- MHLW Panel to Continue Discussions on Inclusion of Zoster and Trivalent Vaccines in Public Vaccination Programs
November 20, 2017
- LDP Lawmakers Air Concerns over Govt’s Drug Pricing Plans: Social Security Taskforce
November 20, 2017
- Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April
November 20, 2017
- MHLW Panel Members Call for Tougher Regulations on Drug Rep Activities
November 17, 2017
- Annual Re-Pricing Likely to Start in FY2021 for Scope of Products Defined in 2020
November 17, 2017
- Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs
November 17, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…